Inclusion Criteria:  - Male or female ≥18 years of age  Informed consent Primary reason for admission to hospital is worsening HF meeting the European Society of Cardiology (ESC) definition.14 Diuretic Resistance as defined as: Lack of weight loss or absence of a negative fluid balance (as defined above) over the preceding 24 hours despite treatment with high dose IV loop diuretic (equivalent of ≥160mg IV furosemide in 24 hours) Plasma BNP ≥ 100 pg/mL or plasma NT-proBNP ≥ 400 pg/mL in current hospital admission eGFR <60 ml/min/1.73m2 required within 24 hours before randomisation Ongoing clinical evidence of congestion: pitting peripheral oedema and/or ascites and/or elevated jugular venous pressure, and/or radiographic or ultrasonic evidence of pulmonary congestion Expected hospital length of stay >3 days  Exclusion Criteria:  Inability to give informed consent e.g. due to significant cognitive impairment  Intravascular volume depletion based on investigator's clinical assessment eGFR <20 mL/min/1.73 m2 Alternative explanation for worsening renal function such as obstructive nephropathy, contrast induced nephropathy, or acute tubular necrosis Enrollment in another randomised clinical trial involving medical or device-based interventions (co-enrolment in observational studies is permitted) Women of child-bearing potential History of allergy to SGLT2i or thiazide or thiazide-like diuretics or any of the excipients Hypertrophic obstructive cardiomyopathy (HOCM) or significant valvular disease in whom surgical or percutaneous repair or replacement may be considered. SGLT2i, thiazide or thiazide-like diuretics administration in the previous 48 hours prior to randomisation Active genital tract infections Anyone who, in the investigators' opinion, is not suitable to participate in the trial for other reasons